MetaADEDB 2.0 @ LMMD
Symptom recurrence
(UMLS:C4524105)
UMLS ID:
C4524105
MeSH ID:
N/A
Synonym(s)
1.
Symptom recurrence
Associated Drug(s)
NameNumber of ReportsReference(s)Data Source
1RifaximinFAERS: 9US FAERS
2BudesonideFAERS: 6US FAERS
3apremilastFAERS: 3US FAERS
4AustedoFAERS: 2US FAERS
5DichlorphenamideFAERS: 2US FAERS
6EstradiolFAERS: 2US FAERS
7Glatiramer AcetateFAERS: 2US FAERS
8LamotrigineFAERS: 2US FAERS
9ValacyclovirFAERS: 2US FAERS
10Valproic AcidFAERS: 2US FAERS
11VigabatrinFAERS: 2US FAERS
12tofacitinibFAERS: 2US FAERS
132-(Tert-butylamino)-1-(3-chlorophenyl)propan-1-one;hydron;chlorideFAERS: 1US FAERS
144-AminopyridineFAERS: 1US FAERS
15AlbuterolFAERS: 1US FAERS
16AnidulafunginFAERS: 1US FAERS
17AripiprazoleFAERS: 1US FAERS
18Breo ElliptaFAERS: 1US FAERS
19ClozapineFAERS: 1US FAERS
20DabigatranFAERS: 1US FAERS
21DehydroepiandrosteroneFAERS: 1US FAERS
22Lisdexamfetamine DimesylateFAERS: 1US FAERS
23MechlorethamineFAERS: 1US FAERS
24MesalamineFAERS: 1US FAERS
25MetoprololFAERS: 1US FAERS
26Nexium 24hrFAERS: 1US FAERS
27OseltamivirFAERS: 1US FAERS
28OxcarbazepineFAERS: 1US FAERS
29PrednisoneFAERS: 1
Canada Vigilance: 3
Canada Vigilance
US FAERS
30PregabalinFAERS: 1US FAERS
31PrezcobixFAERS: 1US FAERS
32Pyridostigmine BromideFAERS: 1US FAERS
33TadenanFAERS: 1US FAERS
34TamsulosinFAERS: 1US FAERS
35ThyroxineFAERS: 1US FAERS
36TicagrelorFAERS: 1US FAERS
37ValacyclovirFAERS: 1US FAERS
38baricitinibFAERS: 1US FAERS
39brexpiprazoleFAERS: 1US FAERS
40fludrocortisone acetateFAERS: 1US FAERS
41lanreotideFAERS: 1US FAERS
42pimecrolimusFAERS: 1US FAERS
43sofosbuvir-velpatasvir drug combinationFAERS: 1US FAERS
44tavaboroleFAERS: 1US FAERS
45teriflunomideFAERS: 1US FAERS
46MoclobemideCanada Vigilance: 2Canada Vigilance
Powered by :

Page last updated at 2020-05-25 10:01:57 (Asia/Shanghai) | You are visitor No. 120241

Copyright © 2019-2020 Laboratory of Molecular Modeling and Design, Shanghai Key Laboratory of New Drug Design, School of Pharmacy, East China University of Science and Technology. All rights reserved.